Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Third-Line Regorafenib and TAS-102 in mCRC

January 30th 2015

Second-Line Therapy for Metastatic CRC

January 30th 2015

Postoperative Therapy for Metastatic CRC

January 30th 2015

Treatment Selection in RAS Wild-Type mCRC

January 30th 2015

Communication Strategies for Newly Diagnosed mCRC

January 30th 2015

Expanded RAS Testing Required in CRC

January 30th 2015

Exercise and Lifestyle Factors in Patients with mCRC

January 30th 2015

Adjuvant Therapy in Stage II Colon Cancer

January 30th 2015

Molecular Testing in Colorectal Cancer

January 30th 2015

Colorectal Cancer Screening and Prevention

January 30th 2015

Targeted Therapies and Immunotherapies Are Transforming Outcomes in Advanced NSCLC

January 28th 2015

Ten or 15 years ago, a diagnosis of advanced nonâ€“ small cell lung cancer (NSCLC) led directly to a discussion of chemotherapy.

Joan Lunden and Dr Patrick Borgen Discuss Imaging and Genetic Testing in Breast Cancer

January 23rd 2015

Joan Lunden talks about imaging technology and genetic testing for the early detection of breast cancer with Roy Firestone and Patrick I. Borgen, MD, in advance of her keynote address at the 32nd Miami Breast Cancer Conference.

Precision Medicine Goes Mainstream

January 22nd 2015

"Precision, personalized, individualized, targeted" - most oncologists are well acquainted with these terms. On Tuesday, President Obama introduced this concept to the nation in his State of the Union Address.

Grant Aims to Deliver First Stem-Cell Immunotherapy in Ovarian Cancer

January 19th 2015

The New York State Stem Cell Science Program recently awarded a 4-year $11.9 million grant to Roswell Park Cancer Institute to fund research and development of a stem-cell based treatment for ovarian cancer.

Expert Discusses Significance of Roche/Foundation Medicine Collaboration

January 15th 2015

Andre Goy, MD, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, sat down with OncLive to discuss the recent merger and what that means for the future of precision medicine.

Final Comments From Panelists on Managing CML

January 14th 2015

Feasibility of TKI Discontinuation in CML

January 14th 2015

Addressing Fluctuating BCR-ABL Levels in CML

January 14th 2015

Utilizing Omacetaxine in Chronic Myeloid Leukemia

January 14th 2015

Ponatinib Effective in Resistant CML

January 14th 2015